Oncotelic Therapeutics, Inc. Chairman and CEO Vuong Trieu filed a Form 4 on October 30, 2026, reporting two open-market purchases of common stock totaling 1,356,990 shares made on October 28 and October 29, 2026.

Key Highlights

  • October 29 purchase: Trieu acquired 1,044,990 shares of common stock at $0.017 per share in his individual capacity from the open market.
  • October 28 purchase: Trieu acquired 312,000 shares of common stock at $0.0185 per share in his individual capacity from the open market.
  • Direct beneficial ownership after transactions: 95,481,309 shares held directly following the October 29 transaction, according to the filing.
  • Indirect ownership via Autotelic Inc.: An additional 16,780,384 shares are held indirectly by Autotelic Inc., per the filing.
  • Indirect ownership via spouse: An additional 6,872,529 shares are held indirectly through Trieu's spouse, according to the filing.
  • Reporting person roles: Trieu is identified in the filing as Director, 10% Owner, and Chairman and CEO of Oncotelic Therapeutics, Inc.

Trieu's Open-Market Purchases of Oncotelic Common Stock on October 28 and 29, 2026

According to the Form 4 filed with the SEC on October 30, 2026, Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, Inc. (OTC:OTLC), reported two separate open-market purchases of the company's common stock. On October 28, 2026, the filing discloses that Trieu purchased 312,000 shares at a price of $0.0185 per share in his individual capacity. The following day, October 29, 2026, he purchased an additional 1,044,990 shares at $0.017 per share, also from the open market and in his individual capacity.

Following the October 28 transaction, the filing reports Trieu's direct beneficial ownership at 94,436,319 shares. After the October 29 transaction, that figure increased to 95,481,309 shares held directly. The filing also discloses indirect holdings of 16,780,384 shares through Autotelic Inc. and 6,872,529 shares held indirectly through his spouse, though these indirect positions are not reported as having changed in connection with the two transactions described.

The Form 4 was filed by one reporting person and bears the signature of Vuong Trieu dated October 30, 2026. No derivative securities transactions were reported in Table II of the filing. The filing does not indicate that either transaction was made pursuant to a Rule 10b5-1(c) plan.

What Was Disclosed

The filing discloses two open-market purchases of Oncotelic Therapeutics common stock by Chairman and CEO Vuong Trieu on October 28 and 29, 2026, totaling 1,356,990 shares, with resulting direct beneficial ownership of 95,481,309 shares.